RESEARCH TRIANGLE PARK — Locus Biosciences, which is developing advanced antibacterial products, has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies.
FierceBiotech is an online daily news service covering the biotech industry. Being recognized by the publication puts the RTP-based company on a shortlist of the most promising private biotechnology companies in the industry.
Earlier this year, Locus landed a major deal with Janssen Pharmaceuticals, opart of Johnson & Johnson. The deal could be worth up to $818 million.
“This year has seen unrivalled scientific talent in the early-stage life sciences world and it has been a pleasure for us at FierceBiotech to speak to all 15 winners and hear their passion, progress and panache,” Ben Adams, senior editor of FierceBiotech said in a release.
Inside the potential $818M Locus Biosciences deal + a CRISPR primer, video
“Each company brought something different, exciting and potentially life-changing for a myriad of patients around the world across a host of diseases and disorders, using cutting-edge science, top-notch teams and a drive to genuinely make the world a better place, despite the risks and challenges that, as ever in biotech, lay ahead.”
RTP-based Locus is developing targeted CRISPR-engineered bacteriophage products. A bacteriophage is a virus that infects bacteria. CRISPR is a gene-editing technology. The Locus Bioscience products kill target bacterial by irreversibly destroying their DNA, while leaving the body’s good bacteria unharmed.
“We are proud to be named to the 2019 Fierce 15 list,” Paul Garofolo, CEO of Locus, said in a statement.
“FierceBiotech has a phenomenal track record of identifying private biotechnology companies that are on the cusp of rapid growth and value creation, and we are pleased to be recognized along with the other promising companies on the list this year.”
Expanding Locus Biosciences moves to new RTP office and lab space
